Abvc Biopharma (ABVC) Net Income (2010 - 2026)

Abvc Biopharma (ABVC) has reported Net Income for 16 consecutive years, with -$640280.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income rose 72.55% year-over-year to -$640280.0; the trailing twelve-month figure through Jun 2026 stood at -$7.1 million (down 62.17% YoY), and the FY2025 full-year result was -$8.4 million, down 59.29% from the prior year.
• Net Income grew to -$640280.0 in Q2 2026 per ABVC's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Net Income topped out at -$487431.0 in Q3 2024 and bottomed at -$6.1 million in Q1 2022.
• Historically, Net Income has averaged -$2.2 million across 5 years, with a median of -$2.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Net Income slumped 409.29% in 2022, then soared 85.53% in 2024.
• Over 5 years, Net Income stood at -$4.5 million in 2022, then surged by 84.44% to -$700309.0 in 2023, then decreased by 13.74% to -$796527.0 in 2024, then slumped by 278.7% to -$3.0 million in 2025, then soared by 78.77% to -$640280.0 in 2026.
• According to Business Quant data, Net Income over the past three periods registered -$640280.0, -$1.3 million, and -$3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.